Kymera Therapeutics price target raised to $140 from $125 at Piper Sandler [Yahoo! Finance]
Kymera Therapeutics, Inc. (KYMR)
Company Research
Source: Yahoo! Finance
Piper Sandler analyst Biren Amin raised the firm's price target on Overweight-rated Kymera Therapeutics ( KYMR ) to $140 from $125 after transfer in analyst coverage. The firm believes Kymera is positioned to be a category leader in oral protein degraders, with early clinical data from its lead STAT6 degrader program supporting the thesis that TPD can deliver biologic-like pathway suppression in a convenient and scalable oral formulation. Collectively, Piper thinks Kymera's combination of first-mover advantage in immunology degraders, oral differentiation versus biologics, and expanding clinical proof supports an attractive risk-reward profile at current levels. Claim 50% Off TipRanks Premium Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news
Show less
Read more
Impact Snapshot
Event Time:
KYMR
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
KYMR alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
KYMR alerts
High impacting Kymera Therapeutics, Inc. news events
Weekly update
A roundup of the hottest topics
KYMR
News
- Kymera Therapeutics Q4 Earnings Call Highlights [Yahoo! Finance]Yahoo! Finance
- Kymera Therapeutics (KYMR) had its "overweight" rating reaffirmed by Morgan Stanley.MarketBeat
- Kymera Therapeutics (KYMR) had its "outperform" rating reaffirmed by Royal Bank Of Canada.MarketBeat
- Kymera Therapeutics (KYMR) had its price target lowered by BTIG Research from $138.00 to $134.00. They now have a "buy" rating on the stock.MarketBeat
- Kymera Therapeutics (KYMR) had its price target raised by Piper Sandler from $125.00 to $140.00. They now have an "overweight" rating on the stock.MarketBeat
KYMR
Earnings
- 2/26/26 - Miss
KYMR
Sec Filings
- 2/26/26 - Form 8-K
- 2/26/26 - Form 424B3
- 2/26/26 - Form 424B5
- KYMR's page on the SEC website